Form 4: Rapport Therapeutics CSO Sells Shares via 10b5-1 Plan

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold a total of 8,500 shares of common stock on December 15, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported transactions involving the sale of common stock.
• On December 15, 2025, Bredt sold 7,704 shares of common stock at a weighted average price of $29.9469 per share.
• On the same date, an additional 796 shares of common stock were sold at a weighted average price of $30.6772 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on December 12, 2024.
• Following these sales, David Bredt beneficially owns 392,642 shares of Rapport Therapeutics common stock.

Sentiment

Score: 4

Explanation: The Chief Scientific Officer sold a significant number of shares, which can be perceived negatively by investors. However, the sales were pre-scheduled under a Rule 10b5-1 plan, which mitigates some of the negative sentiment as it suggests a planned liquidity event rather than a reaction to new adverse information.

Positives

• The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024, indicating a pre-scheduled transaction rather than a reaction to immediate news.

Negatives

• Chief Scientific Officer David Bredt sold a total of 8,500 shares of common stock.
• The sales reduce the direct beneficial ownership of a key executive in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May experience negative sentiment due to insider selling, although the pre-arranged nature of the sales under a 10b5-1 plan may temper concerns.

Key Dates

Recommendation

While the Chief Scientific Officer sold shares, the transaction was executed under a pre-arranged 10b5-1 trading plan, suggesting a planned diversification or liquidity event rather than a reaction to new negative information. The remaining beneficial ownership is still substantial. Investors should monitor future insider activity and company performance, but this single Form 4 does not warrant a change in investment thesis at this time.

Keywords

Rapport Therapeutics, RAPP, Insider Trading, Form 4, Stock Sale, David Bredt, Chief Scientific Officer, 10b5-1 Plan